Isavuconazole and Pimozide: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Moderate CYP3A inhibition may increase pimozide concentrations.
Clinical significance and safety
Isavuconazole and Pimozide: Moderate CYP3A inhibition may increase pimozide concentrations. This combination is contraindicated under the cited pimozide product information. It requires prompt prescriber or pharmacist review; changing doses without that review is not an appropriate workaround. Changes in exposure can affect tolerability or treatment response. The prescriber must check the exact inhibitor, formulation, dose and timing against the cited product information; doses should not be adjusted without that review. The restriction follows the cited Turkish pimozide label. Isavuconazole is a moderate CYP3A inhibitor, not a strong inhibitor or a QT-prolonging drug; the concern here is metabolism. Ask a pharmacist or prescriber to review the full medicine list before adding or changing treatment.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.